36 -2 (34/1) 2021 — Musayeva D.M., Ochilov A.K. — PECULIARITIES OF THE CYP2C19 GENOTYPE AND INFLUENCE ON THE EFFECTIVENESS OF PHARMACOTHERAPY

PECULIARITIES OF THE CYP2C19 GENOTYPE AND INFLUENCE ON THE EFFECTIVENESS OF PHARMACOTHERAPY

Musayeva D.M., Bukhara State Medical Institute

Ochilov A.K. Bukhara State Medical Institute

Resume

The article presents the results of a genotypic study of patients with chronic gastritis in the Bukhara region by polymorphism of the CYP2C19 gene for the polymorphic marker G681A. It turned out that in the present region, patients with the G/G genotype prevail and, according to the prevalence, type B of chronic gastritis associated with Helicobacter pylori prevails.

Key words: CYP2C19 gene, polymorphism, chronic gastritis, polymorphic marker G681A of the CYP2C19 gene, proton pump inhibitors.

First page

194

Last page

199

For citation: Musayeva D.M., Ochilov A.K. Peculiarities of the cyp2c19 genotype and influence on the effectiveness of pharmacotherapy //New Day in Medicine 2(34/1)2021 194-199 https://cutt.ly/fbDHzlK

LIST OF LITERATURE

1. Arvanitidis K. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population // К. Arvanitidis, G. Ragia, M. Iordanidou et al. // Fundam. Clin. Pharmacol. 2007. Vol. 21 №4. P. 419 – 426.
2. Dawood S. Pharmacology, pharmacogenetics, and pharmacoepidemiology: three ps of individualized therapy. Cancer Invest. 2009. Oct. Vol.27, №8. P. 809-815.
3. Efrén Martínez-Quintana, Fayna Rodríguez-González, José María Medina-Gil, Paloma Garay-Sánchez, Antonio Tugores // Actividad de CYP2C19 y factores de riesgo cardiovascular en pacientes con síndrome coronario agudo. Medicina Clínica. Volume 149. Issue 6. 2017. Pages 235-239.
4. Gaikovitch E.A., Cascorbi I., Mrozikie- wicz P.M., Brockmöller J., Frötschl R., Köpke K., Gerloff T., Chernov J.N., Roots I. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population//Eur. J. Clin. Pharmacol. 2003, Aug. Vol.59, №4. P. 303-312.
5. Gomez A., Ingelman-Sundberg M. Pharmacoepigenetics: its role in interindividual differences in drug response//Clin. Pharmacol. Ther. 2009, Apr. Vol.85, №4. P. 426-430.
6. Isakov V.A. Farmakogeneticheskiy analiz metabolizma i klinicheskoy effektivnosti ingibitorov protonnogo nasosa / V. A. Isakov // Klin. farmakol. ter. 2003. № 1. S. 32 – 37.
7. Kantemirova B.I., Griganov V.I., Dubina D.SH., Aliyeva Z.G. // Polimorfizm gena CYP2C19 u detey, prozhivayushchikh v astrakhanskom regione. Meditsinskiy vestnik Bashkortostana. Tom 7 №4 2012. 29-32 S.
8. Kitayeva Ye. Yu., Shprakh V.V., Mirzayev K.B., Ryzhikova K.A., Shuyev G.N., Sozayeva Zh.A., Pimenova Yu.A., Kogay V.V., Sychev D.A. //Chastota polimorfizmov genov CYP2C19 i ABCB1, assotsiirovannykh s izmeneniyem antiagregantnogo deystviya klopidogrela, u russkikh i buryat. Sibirskoye meditsinskoye obozreniye. 2018 №3 43-50 S.
9. Kukes V.G. Metabolizm lekarstvennykh sredstv: kliniko-farmakologicheskiye aspekty. – M.: Reafarm, 2004. – S. 113-120.
10.  Ieiri I., Higuchi S. Pharmacogenomics: inter-ethnic and intra-ethnic differences in pharmacokinetic and pharmacodynamic profiles of clinically relevant drugs //Yakugaku Zasshi. 2009, Feb. Vol.129, №2. P. 231-235.
11. Мiguel A. López-García, Iris A. Feria-Romero, Héctor Serrano, Darío Rayo-Mares, Pietro Fagiolino, Marta Vázquez, Consuelo Escamilla-Núñez, Israel Grijalva, David Escalante-Santiago, Sandra Orozco-Suarez // Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy. Pharmacological Reports. Volume 69. Issue 3. 2017. Pages 504-511
12. Musayeva D.M., Ochilov A.K., Ochilova G.S. Korrektsiya farmakometaboliziruyushchey funktsii pecheni antioksidantami //Dostizheniya nauki i obrazovaniya. – 2018. – №. 10 (32).
13. Nebert D.W., Dalton T.P. The role of cyto- chrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. //Nat Rev Cancer. 2006. Dec; 6(12):947-60.
14. Ochilov A.K. Vazhnost’ tsitokhromov Р450 dlya gastroenterologii // Novyy den’ v meditsine. – 2020. – №2 (30/2). – S. 57-59.
15. Ochilova G.S. Kharakteristika glikoproteina-Р kak belka transportera lekarstvennykh veshchestv  // New Day Medicine. – 2020. – №2 (30/2). – S. 60-63.
16. Ochilov A. K., Musayeva D. M. LECHENIYe KHRONICHESKOGO GASTRITA V ZAVISIMOSTI OT ALLEL’NYKH VARIANTOV GENA CYP2C19 //dlya provedeniya I-mezhdunarodnoy nauchno-prakticheskoy onlayn-konferentsii «Aktual’nyye voprosy meditsinskoy nauki v XXI veke». – 2019. – S. 267.
17.  Ochilova D.A., Rakhmonkulova N.G., Effectiveness of combination therapy in the treatment of hypertensive disease//New Day in Medicine 1(29)2020 305-307 https://cutt.ly/hvNY7VE
18. Ochilov A.K., Musayeva D.M. Osobennosti gena CYP2S19 dlya induvidualizitsii farmakoterapii // Novyy Den’ v Meditsine 1 (29) 2020. 65-68 s.
19. Ochilov A.K., G.S.Ochilova. “Znacheniye gena CYP2C19 v farmakoterapii pri khronicheskikh gastritakh» // Problemy biologii i meditsiny, 2019, № 4 (113) 250-252 s.
20. Ochilov A.K., Ochilova G.S. Klinicheskaya znachimost’ polimorfizmov gena CYP2C19 // Universitetskaya nauka: vzglyad v budushcheye. Sbornik nauchnykh trudov po materialam Mezhdunarodnoy nauchnoy konferentsii, posvyashchennoy 85-letiyu Kurskogo gosudarstvennogo meditsinskogo universiteta (7 fevralya 2020 goda) Tom I. 2020. 376-379 S.